Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Haemopoietic Growth Factors

Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects

Bone Marrow Transplantation volume 26, pages 939–946 (2000)Cite this article

Abstract

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) (lenograstim) was administered to healthy subjects at doses of 2, 5 and 10 μg/kg/day for 5 days (twice a day subcutaneously) to examine the optimal dose and schedule of lenograstim in mobilizing peripheral blood progenitor cells (PBSC) for allogeneic transplantation. Lenograstim administration significantly increased CD34+ cells in a dose-related manner. A significant correlation was observed between the maximal post-dosing counts and the pre-dosing baseline counts of CD34+ cells. Peripheral neutrophils increased markedly by seven to 13 times from the baseline to a peak of approximately 40 000/μl on day 5 for the 5 and 10 μg/kg/day doses. After peak serum concentration (Cmax) was attained 4 h following administration, serum G-CSF declined with time in a log-linear fashion. The Cmax and 12 h area-under-the-curve increased dose dependently, but minimum drug level increased up to day 2 and then decreased until day 5. Clearance decreased with increasing dosage at the first dose, and increased significantly at the last dose. We found a highly significant correlation between absolute neutrophil counts and clearance for each dose. Adverse events most frequently occurred on day 6, with increases of alkaline phosphatase and lactate dehydrogenase and onset of bone pain. Increases of aspartate aminotransferase and alanine aminotransferase occurred as delayed events. Platelet count gradually decreased after the end of drug administration to 57% of the pre-dosing count on day 10, but was still within the normal range. These preliminary results suggest that repeated doses of lenograstim induce mobilization of PBSC in a dose-dependent manner and the pre-dosing baseline count of PBSC may predict the post-dosing maximal mobilization. The drug treatment may cause delayed-onset moderate thrombocytopenia and increased transaminase, and the drug clearance changes in a complex manner during repeated dosing. Bone Marrow Transplantation (2000) 26, 939–946.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Yoshida Y, Hirashima K, Asano S et al. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes Br J Haematol 1991 78: 378–384

    Article  CAS  Google Scholar 

  2. Ohno R, Tomonaga M, Ohshima T et al. A randomized controlled study of granulocyte colony-stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia (JACSG) Int J Hematol 1993 58: 73–81

    CAS  PubMed  Google Scholar 

  3. Kotake T, Miki T, Akaza H et al. Effect of recombinant granulocyte colony-stimulating factor (rhG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer Cancer Chemother Pharmacol 1991 27: 253–257

    Article  CAS  Google Scholar 

  4. Maruyama K, Tsuji K, Tanaka R et al. Characterization of peripheral blood progenitor cells mobilized by nartograstim (N-terminal replaced granulocyte colony-stimulating factor) in normal volunteers Bone Marrow Transplant 1998 22: 313–320

    Article  CAS  Google Scholar 

  5. Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers Blood 1995 86: 4437–4445

    CAS  PubMed  Google Scholar 

  6. Höglund M, Smedmyr B, Simonsson B et al. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHug-CSF Bone Marrow Transplant 1996 18: 19–27

    PubMed  Google Scholar 

  7. Tanaka R, Matsudaira T, Aizawa J et al. Characterization of peripheral blood progenitor cells (PBPC) mobilized by filgrastim (rHuG-CSF) in normal volunteers: dose–effect relationship for filgrastim with the character of mobilized PBPC Br J Haematol 1996 92: 795–803

    Article  CAS  Google Scholar 

  8. Harada M, Nagafuji K, Fujisaki T et al. G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation J Hematother 1996 5: 63–71

    Article  CAS  Google Scholar 

  9. Arbona C, Prosper F, Benet I et al. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC)in normal donors for allogeneic PBPC transplantation Bone Marrow Transplant 1998 22: 39–45

    Article  CAS  Google Scholar 

  10. Majolino I, Cavallaro AM, Bacigalupo A et al. Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian bone marrow transplantation group (GITMO) Haematologica 1997 82: 47–52

    CAS  PubMed  Google Scholar 

  11. Cleaver SA, Goldman JM . Use of G-CSF to mobilise PBPC in normal healthy donors – an international survey Bone Marrow Transplant 1998 21: (Suppl. 3) S29–S31

    Article  Google Scholar 

  12. Ordemann R, Hölig K, Wagner K et al. Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors Bone Marrow Transplant 1998 21: (Suppl. 3) S25–S28

    PubMed  Google Scholar 

  13. To LB, Haylock DN, Simmons PJ et al. The biology and clinical uses of blood stem cells Blood 1997 89: 2233–2253

    CAS  PubMed  Google Scholar 

  14. Anderlini P, Korbling M, Dale D et al. Allogenic blood stem cell transplantation: considerations for donors Blood 1997 90: 903–908

    CAS  PubMed  Google Scholar 

  15. Bensinger WI, Price TH, Dale DC et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis Blood 1993 81: 1883–1888

    CAS  PubMed  Google Scholar 

  16. Stroncek DF, Clay ME, Petzoldt ML et al. Treatment of normal individuals with granulocyte colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells Transfusion 1996 36: 601–610

    Article  CAS  Google Scholar 

  17. Stute N, Santana VM, Rodman JH et al. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children Blood 1992 79: 2849–2854

    CAS  PubMed  Google Scholar 

  18. Ericson SG, Gao H, Gericke GH et al. The role of polymorphonuclear neutrophils (PMNs) in clearance of granulocyte colony-stimulating factor (G-CSF) in vivo and in vitro Exp Hematol 1997 25: 1313–1325

    CAS  PubMed  Google Scholar 

  19. Kearns CM, Wang WC, Stute N et al. Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia J Pediatr 1993 123: 471–479

    Article  CAS  Google Scholar 

  20. Sturgill MG, Huhn RD, Drachtman RA et al. Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: clearance increases in relation to absolute neutrophil count with repeated dosing Am J Hematol 1997 54: 124–130

    Article  CAS  Google Scholar 

  21. Hayashi N, Kinoshita H, Yukawa E et al. Pharmacokinetic and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (lenograstim) administration J Clin Pharmacol 1999 39: 583–592

    Article  CAS  Google Scholar 

  22. Kuwabara T, Kobayashi S, Sugiyama Y . Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor Drug Metab Rev 1996 28: 625–658

    Article  CAS  Google Scholar 

  23. Kuwabara T, Kato Y, Kobayashi S et al. Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans J Pharmacol Exp Ther 1994 271: 1535–1543

    CAS  PubMed  Google Scholar 

  24. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients Blood 1991 77: 400–409

    CAS  PubMed  Google Scholar 

  25. Motojima H, Kobayashi T, Shimane M et al. Quantitative enzyme immunoassay for human granulocyte colony-stimulating factor (G-CSF) J Immunol Meth 1989 18: 187–192

    Article  Google Scholar 

  26. Gibaldi M, Perrier D . Pharmacokinetics 2nd edn. New York: Marcel Dekker 1982

    Google Scholar 

  27. Russell NH, Hunter AE . Peripheral blood stem cells for allogeneic transplantation Bone Marrow Transplant 1994 13: 353–355

    CAS  PubMed  Google Scholar 

  28. Fischer J, Frick M . Steady-state mobilization of PBSC: schedule-dependent effectivity of G-CSF Exp Hematol 1995 23: 869

    Google Scholar 

  29. Terashi K, Oka M, Ohdo S et al. Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients Antimicrob Agents Chemother 1999 43: 21–24

    Article  CAS  Google Scholar 

  30. Redmond III J, Kantor RS, Auerbach HE et al. Extramedullary hematopoiesis during therapy with granulocyte colony-stimulating factor Arch Pathol Lab Med 1994 118: 1014–1015

    Google Scholar 

  31. Lieschke GJ, Burgess AW . Granulocyte colony-stimulating factor and granulocyte–macrophage colony-stimulating factor New Engl J Med 1992 327: 28–35

    Article  CAS  Google Scholar 

  32. Fukushima N, Nishima H, Koishihara Y et al. Enhanced hematopoiesis in vivo and in vitro by splenic stromal cells derived from the mouse with recombinant granulocyte colony-stimulating factor Blood 1992 80: 1914–1922

    CAS  PubMed  Google Scholar 

  33. Litam PP, Friedman HD, Loughram TP . Splenic extramedullary hematopoiesis in a patient receiving intermittently administered granulocyte colony-stimulating factor Ann Intern Med 1993 118: 954–955

    Article  CAS  Google Scholar 

  34. Flazetti F, Aversa F, Minellli O et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor Lancet 1999 353: 555

    Google Scholar 

Download references

Acknowledgements

The authors thank Dr Shigetaka Asano, Department of Hematology/Oncology, The Institute of Medica Science, University of Tokyo for his supervision of this study. We also thank Dr Masayuki Kobayashi, Department of Hematology/Oncology, Jikei University School of Medicine and the staff of Clinical Research and Development Division, Chugai Pharmaceutical Co, Ltd, Tokyo, Japan for their support. The authors also thank the members of Kannondai Clinic, Tsukuba, Japan for their help.

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, Daisan Hospital, Jikei University School of Medicine, Komae, Tokyo, Japan

    S Akizuki, T Inoue, K Sudo & A Ohnishi

  2. Department of Internal Medicine, Daisan Hospital, Jikei University School of Medicine, Komae, Tokyo, Japan

    F Mizorogi, T Inoue & A Ohnishi

Authors
  1. S Akizuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Mizorogi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Sudo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Ohnishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akizuki, S., Mizorogi, F., Inoue, T. et al. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects. Bone Marrow Transplant 26, 939–946 (2000). https://doi.org/10.1038/sj.bmt.1702641

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702641

Keywords

This article is cited by

Search

Advanced search

Quick links